Archive for the ‘RA Education’ Category
-
4 Funny Things about Pain Scale Charts
Pain is one of the most important symptoms of Rheumatoid Arthritis and many other conditions. Pain is the most obviously significant signal that something is wrong. However, pain is also the most difficult symptom to measure. Need for a pain scale Since pain is such an important indicator that something is “wrong,” we ought to [...]
-
Lipstick & Luck: Feeling Fabulous with Rheumatoid Autoimmune Disease
If we try, will we feel fabulous with Rheumatoid Arthritis? Feeling and looking fabulous with RA sells well, but how much can lipstick help? Most people living with Rheumatoid Arthritis have felt the sting of someone suggesting we don’t need to be as sick if we would only try _____. Hearing this can seem harsh, [...]
-
When Treatment for Rheumatoid Arthritis Is Even Worse than the Disease
Yesterday, we discussed the frequently-asked question of the consequences of not treating RA. People also sometimes say they just can’t take Rheumatoid Arthritis treatment any longer because “it’s even worse than the disease.” Why do patients say that and what’s a reasonable response? Let’s be clear about terms: Treatment: medicine used to improve disease activity [...]
-
The Consequences of Not Treating Rheumatoid Arthritis?
Sometimes people ask me whether taking treatment for RA matters. Over the last couple of years, I’ve answered dozens of emails with this question, posted on Facebook last week: “What are the consequences of not treating RA?” Why patients wonder about not treating Rheumatoid Arthritis Since I live with RA myself, I know the validity [...]
-
What Causes Rheumatoid Arthritis Disease to Trigger?
I never asked “why me?” when diagnosed with RA because it’s not my way of thinking. Yet people do ask me “HOW did this happen?”Asking “What triggers RA?” is the multi-billion dollar question! Here’s a summary of what is known at this point. WHAT happens when Rheumatoid Arthritis begins? Researchers have been puzzled for years [...]
-
Pfizer’s JAK inhibitor Tofacitinib EMA Application Validated
Pfizer JAK-3 press release “Pfizer Announces European Medicines Agency Acceptance Of Regulatory Submission For Tofacitinib For The Treatment Of Rheumatoid Arthritis: Pfizer Inc. (NYSE:PFE) announced today that its Market Authorisation Application for tofacitinib (development code CP-690,550), a novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis (RA), has been validated [...]
-
Digging in to the 2011 American College of Rheumatology Scientific Meeting
As I returned from the 2010 American College of Rheumatology Scientific Meeting last year, I painted a picture for you of its significance and the impact it made on me. Those words are still a proper backdrop as we review the events of the 2011 meeting: Context, Care, & Complicated and I hope you’ll read [...]
-
Mayo Clinic Video Interview: Patients at ACR Scientific Meeting
Some of you may be puzzled about what I’m doing in Chicago. So here’s a brief summary and a video interview with Mayo Clinic News Blog telling why patients are interested in a scientific meeting like the ACR Scientific Meeting. What happens at the American College of Rheumatology Scientific Meeting? “The ACR/ARHP Annual Scientific Meeting [...]
Subscribe to feed
